On June 28, 2024, Chengdu Maxvax Biotechnology LLC (hereinafter referred to as “Maxvax”) announced that its application for a clinical trial of a new vaccine - recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) - has been approved by China’s Center for Drug Evaluation (CDE). The vaccine is being independently developed by Maxvax and the application was co-filed by Maxvax and its wholly owned subsidiary. Targeting prevention of lower respiratory tract diseases in older adults caused by Respiratory Syncytial Virus (RSV), the vaccine incorporates Maxvax’s innovative adjuvant technology that is designed to enhance cellular immune responses in older adults.

What you need to know about RSV

RSV is a single-stranded RNA virus that can infect people of all ages, especially the elderly and young kids. RSV infection can cause severe clinical symptoms and has a high disease burden and case fatality rate similar to influenza in older adults. Natural RSV infection does not produce long-lasting immunity, so individuals are prone to recurrent infections, making RSV disease one of the most serious public health challenges globally. Vaccination is the preferred clinical intervention to prevent and lower respiratory tract disease caused by RSV but currently there is no in-country developed RSV vaccine on the market.

What’s special about Maxvax’s RSV vaccine?

The recombinant adjuvanted RSV vaccine (CHO cell) being developed by Maxvax adopts the most advanced technology in the field of RSV vaccine research and is stabilized pre F glycoprotein. Pre-clinical studies have shown that this product has a strong safety and immunogenicity profile, inducing potent cell-mediated immune responses and high titers of neutralizing antibodies against both RSV A and B strains.

About Maxvax

Since its inception, Maxvax has focused on the research, development, production, and commercialization of innovative human and veterinary (including pet) vaccines. Maxvax has built an extensive pipeline of innovative vaccines incorporating novel adjuvant and recombinant protein technology platforms. In the field of human vaccines, Maxvax has laid out a diversified product development pipeline, including preventative and therapeutic vaccines for major infectious diseases and cancers. Maxvax completed construction of a commercial vaccine manufacturing facility in 2023 and has laid out plans for further capacity building in the near future.